Philip G De Groot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11081335/publications.pdf

Version: 2024-02-01

163 papers	13,419 citations	22099 59 h-index	22102 113 g-index
164 all docs	164 docs citations	164 times ranked	9959 citing authors

#	Article	IF	Citations
1	Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism, 2002, 46, 1019-1027.	6.7	1,736
2	Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kruî‚ppel-like factor (KLF2). Blood, 2002, 100, 1689-1698.	0.6	606
3	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology, 2006, 44, 53-61.	3.6	534
4	Structures of Glycoprotein Ibalpha and Its Complex with von Willebrand Factor A1 Domain. Science, 2002, 297, 1176-1179.	6.0	524
5	Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurology, The, 2009, 8, 998-1005.	4.9	370
6	IgG antibodies that recognize epitope Gly40-Arg43 in domain I of Î²2â€“glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood, 2005, 105, 1540-1545.	0.6	369
7	Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood, 2010, 116, 113-121.	0.6	309
8	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology, 2001, 121, 131-139.	0.6	264
9	Glycation Induces Formation of Amyloid Cross-Î² Structure in Albumin. Journal of Biological Chemistry, 2003, 278, 41810-41819.	1.6	248
10	Î²2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 2010, 116, 1336-1343.	0.6	247
11	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood, 2005, 105, 1102-1105.	0.6	246
12	Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood, 2009, 113, 526-534.	0.6	239
13	Antiphospholipid syndrome. Nature Reviews Disease Primers, 2018, 4, 17103.	18.1	233
14	Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus. Thrombosis and Haemostasis, 1996, 76, 0916-0924.	1.8	220
15	Haemostatic abnormalities in patients with liver disease. Journal of Hepatology, 2002, 37, 280-287.	1.8	212
16	Î²2-glycoprotein Iâ€“dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood, 2004, 104, 3598-3602.	0.6	212
17	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Journal of Thrombosis and Haemostasis, 2020, 18, 2828-2839.	1.9	211
18	Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. Journal of Clinical Investigation, 2008, 118, 3208-18.	3.9	205

#	Article	IF	Citations
19	Pathogenic anti-Î²2-glycoprotein I antibodies recognize domain I of Î²2-glycoprotein I only after a conformational change. Blood, 2006, 107, 1916-1924.	0.6	199
20	Dimers of Î²2-Glycoprotein I Increase Platelet Deposition to Collagen via Interaction with Phospholipids and the Apolipoprotein E Receptor 2â€². Journal of Biological Chemistry, 2003, 278, 33831-33838.	1.6	196
21	Cellâ€“collagen interactions: the use of peptide Toolkits to investigate collagenâ€“receptor interactions. Biochemical Society Transactions, 2008, 36, 241-250.	1.6	170
22	Antiphospholipid antibodies promote leukocyteâ€“endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via Î²2GPI and apoER2. Journal of Clinical Investigation, 2011, 121, 120-131.	3.9	165
23	Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood, 2002, 99, 175-179.	0.6	159
24	P-selectin glycoprotein ligand 1 and Î²2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood, 2006, 108, 3746-3752.	0.6	152
25	Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. Journal of Allergy and Clinical Immunology, 2016, 138, 1414-1423.e9.	1.5	146
26	Lupus Anticoagulant Activity Is Frequently Dependent on the Presence of Î²2-Glycoprotein I. Thrombosis and Haemostasis, 1992, 67, 499-502.	1.8	138
27	An Experimental Model to Study the in Vivo Survival of von Willebrand Factor. Journal of Biological Chemistry, 2004, 279, 12102-12109.	1.6	132
28	A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III. Thrombosis and Haemostasis, 1996, 75, 950-958.	1.8	131
29	A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood, 2005, 106, 3035-3042.	0.6	127
30	The significance of autoantibodies against Î²2-glycoprotein I. Blood, 2012, 120, 266-274.	0.6	126
31	The low-frequency allele of the platelet collagen signaling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood, 2003, 101, 4372-4379.	0.6	124
32	Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nature Medicine, 1999, 5, 107-111.	15.2	123
33	Correlation between antiphospholipid antibodies that recognize domain I of Î²2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood, 2007, 109, 1490-1494.	0.6	121
34	Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood, 2004, 103, 903-911.	0.6	116
35	A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides. Blood, 2006, 108, 3753-3756.	0.6	112
36	Role of ADP Receptor P2Y12in Platelet Adhesion and Thrombus Formation in Flowing Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 686-691.	1.1	111

#	Article	IF	Citations
37	Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood, 2011, 117, 1408-1414.	0.6	109
38	Î²2-Glycoprotein I inhibits von Willebrand factorâ€“dependent platelet adhesion and aggregation. Blood, 2007, 110, 1483-1491.	0.6	108
39	Recombinant factor VIIa enhances deposition of platelets with congenital or acquired Î±IIbÎ²3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factorâ€“independent thrombin generation. Blood, 2003, 101, 1864-1870.	0.6	107
40	Î²2-Glycoprotein I: a novel component of innate immunity. Blood, 2011, 117, 6939-6947.	0.6	101
41	Thrombocytopenia and Release of Activated von Willebrand Factor during EarlyPlasmodium falciparumMalaria. Journal of Infectious Diseases, 2007, 196, 622-628.	1.9	98
42	Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood, 2010, 115, 5069-5079.	0.6	97
43	Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis. PLoS Medicine, 2008, 5, e97.	3.9	96
44	A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the Î±IIbÎ²3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood, 2008, 111, 3407-3414.	0.6	94
45	Immune responses against domain I of Î²2-glycoprotein I are driven by conformational changes: Domain I of Î²2-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis and Rheumatism, 2011, 63, 3960-3968.	6.7	94
46	Mechanisms of Disease: antiphospholipid antibodiesâ€”from clinical association to pathologic mechanism. Nature Clinical Practice Rheumatology, 2008, 4, 192-199.	3.2	81
47	Recombinant factor VIIa restores aggregation of Î±IIbÎ²3-deficient platelets via tissue factorâ€“independent fibrin generation. Blood, 2004, 103, 1720-1727.	0.6	76
48	Simple Collagen-Like Peptides Support Platelet Adhesion Under Static But Not Under Flow Conditions: Interaction Via Î±2Î²1 and von Willebrand Factor With Specific Sequences in Native Collagen Is a Requirement to Resist Shear Forces. Blood, 1998, 91, 3808-3816.	0.6	75
49	Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Reviews, 2008, 22, 93-105.	2.8	74
50	Dimers of Î²2-Glycoprotein I Mimic thein Vitro Effects of Î²2-Glycoprotein I-Anti-Î²2-glycoprotein I Antibody Complexes. Journal of Biological Chemistry, 2001, 276, 3060-3067.	1.6	72
51	Platelet Thrombus Formation on Collagen at High Shear Rates Is Mediated by von Willebrand Factorâ€“Glycoprotein Ib Interaction and Inhibited by von Willebrand Factorâ€“Glycoprotein IIb/IIIa Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1661-1667.	1.1	70
52	The glycoprotein Ib-IX-V complex contributes to tissue factorâ€“independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood, 2008, 112, 3227-3233.	0.6	69
53	Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I. Current Rheumatology Reports, 2011, 13, 70-76.	2.1	69
54	Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology, 2002, 35, 616-621.	3.6	68

#	Article	IF	Citations
55	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2Bâ€“associated thrombocytopenia. Blood, 2013, 122, 2893-2902.	0.6	68
56	Î²2-Glycoprotein I, the playmaker of the antiphospholipid syndrome. Clinical Immunology, 2004, 112, 161-168.	1.4	67
57	The Impact of the Fibrinolytic System on the Risk of Venous and Arterial Thrombosis. Seminars in Thrombosis and Hemostasis, 2009, 35, 468-477.	1.5	65
58	Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. British Journal of Haematology, 2009, 145, 121-127.	1.2	62
59	The Binding Site in Î²2-Glycoprotein I for ApoER2â€² on Platelets Is Located in Domain V. Journal of Biological Chemistry, 2005, 280, 36729-36736.	1.6	61
60	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood, 2007, 109, 2430-2437.	0.6	61
61	The presence of active von Willebrand factor under various pathological conditions. Current Opinion in Hematology, 2007, 14, 284-289.	1.2	61
62	Quantitative proteomics analysis reveals similar release profiles following specific PAR-1 or PAR-4 stimulation of platelets. Cardiovascular Research, 2014, 103, 140-146.	1.8	61
63	Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood, 2010, 115, 4870-4877.	0.6	60
64	Identification of Coagulation Factor XI as a Ligand for Platelet Apolipoprotein E Receptor 2 (ApoER2). Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1602-1607.	1.1	57
65	ApoE Receptor 2 Mediation of Trophoblast Dysfunction and Pregnancy Complications Induced by Antiphospholipid Antibodies in Mice. Arthritis and Rheumatology, 2016, 68, 730-739.	2.9	56
66	Antiphospholipid Syndromeâ€“Not a Noninflammatory Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 607-614.	1.5	55
67	Platelet adhesion to collagen in healthy volunteers is influenced by variation of both Î±2Î²1 density and von Willebrand factor. Blood, 2000, 96, 1433-1437.	0.6	51
68	A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thrombosis Research, 1998, 92, S43-S46.	0.8	48
69	Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clinical Chemistry and Laboratory Medicine, 2007, 45, 187-9.	1.4	45
70	Antiphospholipid antibodies â€" We are not quite there yet. Blood Reviews, 2011, 25, 97-106.	2.8	45
71	Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Practice and Research in Clinical Rheumatology, 2017, 31, 334-341.	1.4	41
72	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica, 2019, 104, 819-826.	1.7	40

#	Article	IF	Citations
73	Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network. Journal of Biological Chemistry, 2014, 289, 35979-35986.	1.6	38
74	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thrombosis and Haemostasis, 2005, 94, 1341-1343.	1.8	37
75	Twenty-two Years of Failure to Set Up Undisputed Assays to Detect Patients with the Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2008, 34, 347-355.	1.5	37
76	In Vitro Studies of Antiphospholipid Antibodies and Its Cofactor, Î²2-Glycoprotein I, Show Negligible Effects on Endothelial Cell Mediated Protein C Activation. Thrombosis and Haemostasis, 1991, 66, 666-671.	1.8	37
77	Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs. PLoS ONE, 2013, 8, e71402.	1.1	36
78	Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue. PLoS Pathogens, 2019, 15, e1007500.	2.1	36
79	Fibrinolysis and the risk of venous and arterial thrombosis. Current Opinion in Hematology, 2007, 14, 242-248.	1.2	35
80	New Insights into the Role of Erythrocytes in Thrombus Formation. Seminars in Thrombosis and Hemostasis, 2014, 40, 072-080.	1.5	35
81	The Inter-Relationship of Platelets with Interleukin-1Î²-Mediated Inflammation in Humans. Thrombosis and Haemostasis, 2018, 118, 2112-2125.	1.8	35
82	Evolutionary conservation of the lipopolysaccharide binding site of Î²2-glycoprotein I. Thrombosis and Haemostasis, 2011, 106, 1069-1075.	1.8	34
83	From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndrome. Thrombosis Research, 2013, 132, 319-326.	0.8	34
84	Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood, 2009, 114, 3656-3661.	0.6	33
85	The Lupus Anticoagulant Paradox. Seminars in Thrombosis and Hemostasis, 2018, 44, 445-452.	1.5	33
86	8 Antiphospholipid antibodies: Specificity and pathophysiology. Best Practice and Research: Clinical Haematology, 1993, 6, 691-709.	1.1	30
87	Regulation of Platelet Adhesion to the Vessel Wall. Annals of the New York Academy of Sciences, 1994, 714, 190-199.	1.8	30
88	Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9083-9087.	3.3	30
89	Platelet Interaction with the Vessel Wall. Handbook of Experimental Pharmacology, 2012, , 87-110.	0.9	30
90	Antiphospholipid antibodies: update on detection, pathophysiology, and treatment. Current Opinion in Hematology, 2004, 11, 165-169.	1.2	27

#	Article	IF	Citations
91	Glycoprotein Ibî±â€“Mediated Platelet Adhesion and Aggregation to Immobilized Thrombin Under Conditions of Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 670-675.	1.1	27
92	Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome. Thrombosis and Haemostasis, 2021, 121, 1220-1227.	1.8	27
93	Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?. Thrombosis and Haemostasis, 2014, 112, 736-742.	1.8	26
94	Antiâ€“Domain I Î²2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. journal of applied laboratory medicine, The, 2020, 5, 1242-1252.	0.6	24
95	The Future of Antiphospholipid Antibody Testing. Seminars in Thrombosis and Hemostasis, 2012, 38, 412-420.	1.5	23
96	Contact System Activation on Endothelial Cells. Seminars in Thrombosis and Hemostasis, 2014, 40, 887-894.	1.5	23
97	Antiâ€Î²2â€glycoprotein I and antiâ€prothrombin antibodies cause lupus anticoagulant through different mechanisms of action. Journal of Thrombosis and Haemostasis, 2021, 19, 1018-1028.	1.9	22
98	Mechanisms of anti-phospholipid antibody formation and action. Thrombosis Research, 2011, 127, S40-S42.	0.8	21
99	Platelets as pivot in the antiphospholipid syndrome. Blood, 2014, 124, 475-476.	0.6	21
100	Glycated Proteins Modulate Tissueâ€“Plasminogen Activator-Catalyzed Plasminogen Activation. Biochemical and Biophysical Research Communications, 1997, 240, 595-601.	1.0	20
101	Detection of antiâ€domain I antibodies by chemiluminescence enables the identification of highâ€risk antiphospholipid syndrome patients: A multicenter multiplatform study. Journal of Thrombosis and Haemostasis, 2020, 18, 463-478.	1.9	20
102	The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thrombosis and Haemostasis, 2011, 106, 165-171.	1.8	19
103	Targeted Phosphotyrosine Profiling of Glycoprotein VI Signaling Implicates Oligophrenin-1 in Platelet Filopodia Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1538-1543.	1.1	19
104	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. Scientific Reports, 2016, 6, 26306.	1.6	19
105	Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO caseâ€“control study. British Journal of Haematology, 2012, 156, 252-258.	1.2	18
106	Platelet dysfunction contributes to bleeding complications in patients with probable leptospirosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005915.	1.3	18
107	Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor. PLoS ONE, 2019, 14, e0211961.	1.1	18
108	The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Current Opinion in Infectious Diseases, 2005, 18, 205-210.	1.3	17

#	Article	IF	Citations
109	The influence of the pulsatility of the blood flow on the extent of platelet adhesion. Thrombosis Research, 2008, 121, 821-825.	0.8	17
110	Long-term treated HIV infection is associated with platelet mitochondrial dysfunction. Scientific Reports, 2021, 11, 6246.	1.6	17
111	Pathological Anti-Î²2-Glycoprotein I Antibodies Disrupt the Anticoagulant Activity of Annexin A5: A Possible Explanation for the Lupus Anticoagulant Paradox.. Blood, 2005, 106, 135-135.	0.6	17
112	Î²2-Glycoprotein I and LDL-receptor family members. Thrombosis Research, 2004, 114, 455-459.	0.8	16
113	Binding of von Willebrand factor and plasma proteins to the eggshell of Schistosoma mansoni. International Journal for Parasitology, 2014, 44, 263-268.	1.3	15
114	Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13. Seminars in Thrombosis and Hemostasis, 2016, 42, 009-017.	1.5	15
115	Fibrinogen and fibrin are novel substrates for Fasciola hepatica cathepsin L peptidases. Molecular and Biochemical Parasitology, 2018, 221, 10-13.	0.5	14
116	Tissue Factorâ€“Independent Effects of Recombinant Factor VIIa on Hemostasis. Seminars in Hematology, 2008, 45, S12-S15.	1.8	12
117	Antiphospholipid Antibodies and the Risk of Stroke in Urban and Rural Tanzania. Stroke, 2016, 47, 2589-2595.	1.0	12
118	Factor VIII Half-Life and Clinical Characteristics of Severe Hemophilia A.. Blood, 2004, 104, 3091-3091.	0.6	12
119	The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. Blood Reviews, 2015, 29, 223-229.	2.8	11
120	Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. Respiratory Medicine, 2020, 171, 106094.	1.3	11
121	Identification of a Role for Apolipoprotein E Receptor 2 as a Platelet Receptor for Factor XI. Blood, 2008, 112, 3914-3914.	0.6	10
122	The functions of the A1A2A3 domains in von Willebrand factor include multimerin 1 binding. Thrombosis and Haemostasis, 2016, 116, 87-95.	1.8	9
123	The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. Platelets, 2017, 28, 567-575.	1.1	9
124	A switch to a raltegravir containing regimen does not lower platelet reactivity in HIV-infected individuals. Aids, 2018, 32, 2469-2475.	1.0	9
125	Thrombocytopenia and Platelet Dysfunction in Acute Tropical Infectious Diseases. Seminars in Thrombosis and Hemostasis, 2018, 44, 683-690.	1.5	9
126	Role of Glycoprotein IIb:IIIa in the Adhesion of Platelets to Collagen Under Flow Conditions. Blood, 1997, 89, 1837-1837.	0.6	7

#	Article	IF	Citations
127	Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells. Journal of Thrombosis and Haemostasis, 2022, 20, 755-766.	1.9	7
128	Increased Platelet Reactivity Is Associated with Circulating Platelet-Monocyte Complexes and Macrophages in Human Atherosclerotic Plaques. PLoS ONE, 2014, 9, e105019.	1.1	6
129	Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. Thrombosis and Haemostasis, 2014, 112, 304-310.	1.8	6
130	Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma. Thrombosis and Haemostasis, 2018, 118, 471-479.	1.8	6
131	The influence of hypoxia on platelet function and plasmatic coagulation during systemic inflammation in humansin vivo. Platelets, 2019, 30, 927-930.	1.1	6
132	Kallikrein augments the anticoagulant function of the protein C system in thrombin generation. Journal of Thrombosis and Haemostasis, 2022, 20, 48-57.	1.9	6
133	Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and nonâ€genetic factors. Journal of Thrombosis and Haemostasis, 2022, 20, 1089-1105.	1.9	6
134	Indications for a protective function of beta2â€glycoprotein <scp>I</scp> in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2012, 159, 94-103.	1.2	5
135	The Relationship between Fractional Flow Reserve, Platelet Reactivity and Platelet Leukocyte Complexes in Stable Coronary Artery Disease. PLoS ONE, 2013, 8, e83198.	1.1	5
136	Higher and lower active circulating VWF levels: different facets of von Willebrand disease. British Journal of Haematology, 2015, 171, 845-853.	1.2	5
137	Implant stability in patients treated with plateletâ€rich fibrin and bovine bone substitute for alveolar ridge preservation is associated with peripheral blood cells and coagulation factors. Clinical and Experimental Dental Research, 2020, 6, 236-243.	0.8	5
138	Binding of Erythrocyte ICAMâ€“4 to the Platelet Activated Integrin Î±IIbÎ²3 leads to a Direct Erythrocyte-Platelet Adhesion Under Venous Flow Shear Rate. Blood, 2012, 120, 105-105.	0.6	5
139	Coagulation activation during air travel is not initiated via the extrinsic pathway. British Journal of Haematology, 2015, 169, 903-905.	1.2	4
140	In vitro uptake of recombinant factor <scp>VII</scp>a by megakaryocytes with subsequent production of platelets containing functionally active drug. British Journal of Haematology, 2017, 178, 482-486.	1.2	4
141	Platelet Integrin Î±IIbÎ²3 Activation is Associated with 25-Hydroxyvitamin D Concentrations in Healthy Adults. Thrombosis and Haemostasis, 2020, 120, 768-775.	1.8	4
142	Plasmatic Coagulation Capacity Correlates With Inflammation and Abacavir Use During Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 711-719.	0.9	4
143	O-Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.. Blood, 2006, 108, 178-178.	0.6	4
144	Untargeted Plasma Metabolomics and Gut Microbiome Profiling Provide Novel Insights into the Regulation of Platelet Reactivity in Healthy Individuals. Thrombosis and Haemostasis, 2022, 122, 529-539.	1.8	3

#	Article	IF	Citations
145	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
146	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
147	Interaction of beta2-Glycoprotein I with Members of the Low Density Lipoprotein Receptor Family.. Blood, 2005, 106, 2646-2646.	0.6	3
148	Mechanism of Action of Recombinant Activated Factor VII. Transfusion Alternatives in Transfusion Medicine, 2003, 5, 5-10.	0.2	2
149	The effects of signal transducer and activator of transcription three mutations on human platelets. Platelets, 2018, 29, 602-609.	1.1	2
150	Serotonin, key to thrombocytopenia in dengue?. Blood, 2019, 133, 2249-2250.	0.6	2
151	Hypofibrinolysis as a Risk Factor for Venous Thrombosis.. Blood, 2006, 108, 272-272.	0.6	2
152	Response to Letter Regarding Article, â€œPlasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathyâ€• Circulation, 2015, 131, e19-20.	1.6	1
153	The antiphospholipid syndrome finally fathomed?. Blood, 2018, 131, 2091-2092.	0.6	1
154	Apolipoprotein E Receptor 2â€² Mediates Pathogenic Effects of Dimeric Î²2glycoprotein I and of Anti-Î²2glycoprotein I Antibodies in Vivo. Blood, 2008, 112, 408-408.	0.6	1
155	What are the Target Cells and Receptors that are Recognized by Antiphospholipid Antibodies?. , 2012, , 103-113.		1
156	Natural Proteins Involved in Antiphospholipid Syndrome. , 2017, , 15-27.		1
157	The Influence of Antiphospholipid Antibodies on the Protein C Pathway. , 2006, , 427-438.		0
158	Platelet Activation Under Conditions of Flow. , 2017, , 651-662.		0
159	Acute Activation of Endothelium Induces Circulation of Active Von Willebrand Factor in HELLP Sydrome.. Blood, 2005, 106, 2658-2658.	0.6	0
160	Identification of the von Willebrand Factor Binding Site in Collagen Using Triple Helical Peptides.. Blood, 2005, 106, 413-413.	0.6	0
161	Caffeic Acid Phenyl Ester, a Component of the Chinese Herb Propolis, Inhibits Platelet Aggregation Via Competition with Fibrinogen for Binding to aIIbb3. Blood, 2008, 112, 5367-5367.	0.6	0
162	Staphylococcal Superantigen-Like 5 Activates Platelets, and Supports Platelet Adhesion Under Flow Conditions, Which Is Mediated by GPIb- Alpha and Alpha-IIb-Beta-3. Blood, 2008, 112, 3922-3922.	0.6	0

#	Article	IF	Citations
163	Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients. Blood, 2010, 116, 545-545.	0.6	0